While antibiotics are being used in some places, causing malignant superbugs to rise, in other parts of the world, people are dying because they cannot use these life-sax drugs.

A study published in Lancet infectious diseases was led by a global antibiotic research and development partnership (Guardup), which is a non-profit, which works to improve access to antibiotics, saw about 1.5 Million Millions of Infections due to carbapenum-resistant gram-resistant (CRGN) bacteria, which India, who saw about 1.5 Million Millions of Infections, which witnessed about 1.5 Million Classes due to carbapenum-resistant gram-resistant (CRGN) bacteria. Brazil, Brazil, Brazil, and Brazil, Brazil, including Brazil.

CRGN bacteria are dangerous as they are resistant to “final-rig.” Antibiotics. These are medicines that are used when all others fail.

Nevertheless, the study found that only 6.9% of patients in these countries received the right treatment.

India carries the heaviest burden

India’s biggest cases were among all the countries studied in India. It also bought 80% of full antibiotic courses. But despite this, only 7.8% of people with CRGN infection received proper treatment.

This indicates a difference between the drug supply and the actual access to treatment.

A complete course of antibiotics means that a patient must take a completely dose to fight infection completely.

Remembering a part of this treatment makes it less effective and more dangerous in the long run.

These drug-resistant bacteria are usually found in water, food, environment and even our own body. They can cause severe infections such as urinary tract infections (UTIs), pneumonia and food poisoning.

Newborn, elderly people and hospital patients are particularly at risk, especially in intensive care units (ICU).

CRGN infection is difficult to treat as bacteria no longer respond to some of the most powerful antibiotics we have. This is the place where the crisis deepens: at places where these infections are increasing, the drugs required for their treatment are either missing or very expensive.

Reach crisis

Over the years, the focus has been focused on the overweight of antibiotics.

Global Access Director of Guardppa Dr. According to Jennifer Kohan, the reality is that many people in low and medium-or-medals with deadly drug-resistant infections are dying “because they may not require antibiotics,” he was quoted by the BBC.

The study saw eight separate intravenous antibiotics that are active against these resistant bacteria.

One of the drugs in the study was the most widely used. But still, only 1 lakh full courses were available in all eight countries, which were much less than 1.5 million people, which they needed.

Why are patients missing?

According to the study, there are many reasons why patients do not get the right treatment.

This can happen because they are not reaching the right hospital or clinic, are not an accurate diagnosis, are not able to reach the right antibiotics or have a high cost of new drugs.

Many of these antibiotics are very expensive for average patients in countries like India.

Without better policies, price regulation and access programs, millions of people will continue to suffer or die unnecessarily.

Clever policies

Experts stated that two things are immediately needed: to prevent antibiotics and misuse of better systems, to provide them inexpensive and available to those who really need them.

But access alone is not enough. The world is also facing the shrinking pipeline of new antibiotics.

With the investment of low companies in antibiotic research, options for treating future infections are limited.

One of the highest burdens of antimicrobial resistance (AMR) in the world in India. But researchers say that the country also has great ability to lead a global fight against drug-resistant infections.

India’s strong pharmaceutical sector is already a leading effort in antibiotic innovation. From developing new drugs to improving diagnostics, there is a head start in the country.

Experts suggest that India can collect and improve local data. This will help identify what is necessary, where there are gaps, and how to fix them. Some states are already trying new models.

For example, Kerala is using a “hub-end-spoke” system, where small clinics receive support from large hospitals in treating complex infections.

Another solution is procurement, where hospitals or state costs drugs together in bulk, reducing the cost. It has worked for cancer drugs and can also be tried for antibiotics.

Finally, the fight against superbugs is not only wisely use of antibiotics, it is also about making sure they are within the reach of all.